Thyrocare Technologies Ltd (THYROCARE) — Board Meeting | 21 September 2026 (2 announcements)

Thyrocare Technologies announced the board approved the sale of its entire 100% stake in radiology subsidiary Nueclear Healthcare Limited to Trovera Healthcare Private Limited for approximately [amount not verified], comprising 42,500 compulsorily convertible preference shares and cash. The transaction includes acquiring these CCPS as part of the consideration and purchasing Gurugram and Hyderabad properties from NHL for [amount not verified]. Shareholder approval and regulatory clearances are required before completion by November 30, 2026.

Thyrocare Technologies announced on September 21, 2026, that its board approved the sale of its entire 100% stake in material subsidiary Nueclear Healthcare Limited to Trovera Healthcare Private Limited, subject to shareholder approval. The transaction includes a fixed share component of 42,500 compulsorily convertible preference shares issued at a premium of Rs. 13,990 per share (totaling Rs. 59.50 crores) and a cash consideration of approximately Rs. 81.90 crores, subject to working capital adjustments. The company will also acquire these CCPS as part of the deal and plans to purchase immovable properties in Gurugram and Hyderabad from NHL for Rs. 20.59 crores to retain operational premises. The sale, valued at approximately Rs. 141.40 crores, aims to allow Thyrocare to focus on its core pathology business by exiting the radiology segment. The transaction requires shareholder approval and is expected to close by November 30, 2026, contingent on regulatory and contractual conditions.